NCT05599672: COAPS

Co-Use of Opioid Medications and Alcohol Prevention Study

Completed NA Results posted Last updated 12 September 2025

What this trial tests

NA trial testing Alcohol-targeted Brief Intervention-Medication Therapy Management in Alcohol Drinking in 112 participants. Completed in 19 August 2024.

Timeline

1 May 2023

Primary endpoint
19 August 2024

19 August 2024

Quick facts

Lead sponsor	University of Utah
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	112
Start date	1 May 2023
Primary completion	19 August 2024
Estimated completion	19 August 2024
Sites	1 location across United States

Drugs / interventions tested

• Alcohol-targeted Brief Intervention-Medication Therapy Management
• Standard medication counseling

Conditions studied

• Alcohol Drinking — all drugs for Alcohol Drinking →
• Opioid Use — all drugs for Opioid Use →

Sponsor

University of Utah

Who can join

18 and older, any sex, with Alcohol Drinking or Opioid Use. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Alcohol Use Reductions Primary · 3 Months. Changes in alcohol use will be assessed by comparing baseline to month 2. Changes in alcohol use will also be assessed by comparing month 2 to month 3.

The investigators will use the Timeline Follow Back to assess alcohol use reductions. This measure is a calendar based assessment that captures a continuous number (counts) of days of substance use. This quantitative measure is both valid and reliable.

<=19% reduction in drinks per day

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	11
Standard Medication Counseling	12

20-24% reduction in drinks per day

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	1
Standard Medication Counseling	1

25-29% reduction in drinks per day

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	1
Standard Medication Counseling	2

>=30% reduction in drinks per day

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	9
Standard Medication Counseling	7

Opioid Medication Use Primary · 3 Months. Changes in medication use will be assessed by comparing baseline to month 2. Changes in medication use will also be assessed by comparing month 2 to month 3.

The investigators will use the Treatment Services Review 6 to assess if the patients decrease their medication use. This measure is a calendar based assessment that captures a continuous number (counts) of days of substance use. This quantitative measure is both valid and reliable.

<=10% reduction in morphine milligram equivalents

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	12
Standard Medication Counseling	17

11-19% reduction in morphine milligram equivalents

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	1
Standard Medication Counseling	0

20-24% reduction in morphine milligram equivalents

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	1
Standard Medication Counseling	0

25-29% reduction in morphine milligram equivalents

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	1
Standard Medication Counseling	1

>=30% reduction in morphine milligram equivalents

Group	Value	95% CI
Alcohol-targeted Brief Intervention-Medication Therapy Management	7
Standard Medication Counseling	4

Sponsor's own description

Previous research, including that of this team, shows that a significant portion of those regularly using opioids-particularly filling opioids at community pharmacies-also are involved in the co-use of alcohol. This study proposes to adapt a previously developed intervention for opioid medication misuse; test its acceptability, feasibility, and preliminary efficacy; and identify barriers and facilitators to large-scale research and system-level implementation. Results of this study will directly inform a fully-powered subsequent multisite trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Co-use of Opioid Medications and Alcohol Prevention Study (COAPS).
   Cernasev A, Hohmeier K, Field C, Gordon AJ, et al · · 2023 · cited 3× · PMID 37728089 · DOI 10.1177/08897077231191840
2. A short communication of pain outcomes following a pharmacist-delivered alcohol and opioid use reduction intervention.
   Cochran G, Broussard G, Wei Y, Field C, et al · · 2026 · PMID 41810313 · DOI 10.1016/j.dadr.2026.100418